儿童间质性肺病中肺纤维化的患病率与疾病轨迹:基于登记的多中心观察研究
该研究基于chILD-EU登记(23个欧洲国家,1071例0-18岁chILD患儿),前瞻性收集2004至2025年数据,采用centralised peer review和CT/肺活检系统评分。
要点
- 纤维化患儿ppFVC较无纤维化者持续低15-20%,随访至8年。
核心结论
- 应用标准化肺纤维化诊断标准可在chILD患者中识别出纤维化患儿。
- 这些患儿肺功能更低、死亡风险增加,可能从抗纤维化治疗中获益。
研究设计与样本
- 基于chILD-EU登记的前瞻性多中心队列研究,覆盖23个欧洲国家。
- 纳入1071例0-18岁chILD患儿,数据收集含centralised peer review及CT和肺活检系统评分。
- 主要结局为fibrosing lung disease的存在与否,依据fibrosisregister或fibrosistrial预设标准判定。
主要发现
- 两种纤维化定义下,纤维化患儿ppFVC在所有随访至8年的访视中持续低15-20%。
关键数值与推荐
- 纤维化判定依据登记预设的fibrosisregister标准或临床试验所用fibrosistrial标准。
- 肺功能以ppFVC评估,纤维化患儿较无纤维化者持续低15-20%。
临床怎么用
- 对chILD患儿可应用标准化纤维化诊断标准识别纤维化亚群。
- 识别出的纤维化患儿需关注肺功能下降和死亡/肺移植风险升高。
- 该类患儿可能作为抗纤维化治疗的候选人群。
局限性
- fibrosistrial标准下生存和HR趋势未达统计学显著性。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary fibrosis is of critical importance in childhood interstitial lung disease (chILD), yet fibrosis prevalence, impact on clinical progression, and survival have not been systematically evaluated. Therefore, we aimed to determine the prevalence of pulmonary fibrosis and its impact on lung function as well as survival in individuals aged 0-18 years. METHODS: Data were extracted from the chILD-EU register, a multicentre cohort study of children and adolescents with chILD from 23 European countries. Data collection included centralised peer review and systematic scoring of CT scans and lung biopsies. The primary outcome was the presence or absence of fibrosing lung disease. Pulmonary fibrosis was determined based on predefined criteria used in the register (fibrosisregister) or in clinical trials (fibrosistrial). Clinical characteristics, disease categories, pulmonary function data, and survival were assessed. This study was registered with ClinicalTrials.gov (NCT02852928) and is ongoing. FINDINGS: Data were collected prospectively between March 3, 2004 and July 23, 2025. Among the 1071 children diagnosed with chILD, 220 of 1071 fulfilled the criteria of fibrosisregister (20·5% [95% CI 18·1-23·0]) and 62 of 534 fulfilled the criteria of fibrosistrial (11·6% [8·9-14·3]). Median age at inclusion was 2·4 years (IQR 0·6-9·2), 570 (53·2%) participants were male and 501 (46·8%) were female, and 882 (76·8%) were European. Pulmonary function, assessed as percent predicted forced vital capacity (ppFVC), in children with fibrosis under both fibrosis definitions was consistently 15-20% lower across all follow-up visits up to 8 years compared with individuals without fibrosing lung disease. Survival after enrolment was lower in children who fulfilled fibrosisregister criteria than in those who did not fulfil fibrosisregister criteria (log-rank p=0·0029; unadjusted hazard ratio (HR) for death or lung transplantation 1·64 [95% CI 1·18-2·28]). The increased hazard of fibrosisregister remained after adjusting for sex, age category, and BMI z-score. A higher BMI z-score was protective for survival with fibrosisregister (HR 0·80). While not statistically significant, children with fibrosistrial criteria had survival and HR trends in the same direction as those with fibrosisregister criteria. INTERPRETATION: The application of standardised criteria for diagnosing pulmonary fibrosis enables identification of affected children among patients with chILD. These children have lower pulmonary function, an increased risk of death, and could benefit from antifibrotic therapies. FUNDING: Deutsche Forschungsgemeinschaft and Boehringer Ingelheim, Germany.
引用
- Griese M, Reu-Hofer S, Ley-Zaporozhan J, et al. Prevalence and disease trajectories of pulmonary fibrosis of childhood interstitial lung disease: a register-based, multicentre observational study. Lancet Respir Med. 2026. PMID: 42341791. doi:10.1016/S2213-2600(26)00052-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。